Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO
Follow-Up May Explain Lower Cytopenias, KOL Says
Executive Summary
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.
You may also be interested in...
Pfizer Touts Elrexfio’s Potential For Community Oncology Use In Myeloma
The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.
Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem
More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.
10 Approvals To Look Out For In Q3 2023
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.